The president and CEO of Leo Pharma AS, Gitte Aabo, is convinced the years up to 2025 will see remarkable progress in the treatment of dermatological diseases, including the development of gene technologies to cure rare skin diseases, the use of biologics in atopic dermatitis to rival the benefits of such drugs in psoriasis seen over the past decade, and the application of precision medicine to the therapeutic area.
Through participating in such breakthroughs, Leo is aiming to become the global leader in the dermatology space, rivalling larger companies...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
